1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Takeda Alliance Boosts Liver Disease Venture Ambys’s $140m Launch

 
• By Ian Haydock

Takeda is investing in newly launched serious liver disease company Ambys Medicines to support the advancement of the US venture’s platform and pipeline, in line with its core strategic therapeutic priorities.

Liver cancer, CT scan upper abdomen.
NEW VENTURE AMBYS EYES NOVEL APPROACHES TO LIVER DISEASE • Source: Shutterstock

Takeda Pharmaceutical Co. Ltd. is providing substantial launch support to a new US venture focusing on novel regenerative approaches to serious liver diseases, in a move the company says aligns with its strategic focus areas. 

The Japanese firm has committed total funding of $100m to Ambys Medicines, including participation in the start-up’s $60m Series A financing and a further $80m in start-up capital, in return for an option to ex-US commercialization rights to the first four

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapy Areas

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.